KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

← catalyst calendar

NCT06384976 · readout ≤ 253 d

Sponsored by Kyverna Therapeutics (industry) · KYTX — their whole pipeline →.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

120estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-09-20

actual

When the study began enrolling

Primary completion

Apr 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2029

estimated

The whole study's end, after follow-up

First posted

2024-04-25

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-01-13

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Multiple Sclerosis, Primary Progressive
Multiple Sclerosis, Secondary Progressive
Multiple Sclerosis
MS

Interventions

Biological: KYV-101
Drug: Standard lymphodepletion regimen
Drug: Anti-CD20 mAB

Primary outcome

what the primary-completion date above is the date OF

To evaluate efficacy of KYV-101

measured at least 12 weeks

Publications

PMID 33636613 — cited as background

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · KYTX's whole pipeline · Catalyst calendar · Every registered study · What changed